DUS4L-BCAP29 readthrough (DUS4L-BCAP29)

DUS4L-BCAP29 readthrough refers to a naturally occurring chimera (readthrough) transcript generated by the transcriptional readthrough between the adjacent DUS4L (dihydrouridine synthase 4 like) and BCAP29 (B cell receptor associated protein 29) genes on chromosome 7. The resulting fusion mRNA encodes a fusion protein that contains sequences from both parental proteins. The transcript and protein exist in normal physiology and are not unique to cancer. The DUS4L portion is involved in tRNA modification (specifically dihydrouridine synthesis), while BCAP29 is implicated in membrane protein transport, apoptosis, and osteoblast differentiation. There is no evidence to suggest this fusion protein is a commonly recognized therapeutic target, nor is it generally referenced as a drug or biomarker target in disease or pharmacology databases. The "readthrough" nomenclature indicates that this is not a canonical single-gene product, but a genomic fusion resulting from transcription across two neighboring genes. No drugs, known mechanisms of drug action, or established biomarker roles have been documented for DUS4L-BCAP29 readthrough in current human biomedical or pharmacological resources. This designation is not considered a standard therapeutic target but rather a naturally occurring transcript and protein fusion, with a physiological (not pathological) presence. If you are looking for information on DUS4L or BCAP29 as independent genes, they have more clearly defined molecular functions, but the fusion readthrough itself is not a therapeutically actionable entity.

Other names

DUS4L-BCAP29 proteinDUS4L-BCAP29